Related Experiment Video
Updated: May 19, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
Published on: June 29, 2021
Analysis of financing of drug programs in allergology in 2020-2024
Krzysztof Nojszewski1, Karina Jahnz-Różyk2,3
1Novartis Poland.
Introduction:
This article presents a detailed analysis of financing of drug programs in allergology in Poland in the years 2020-2024. Polish allergology faces many significant challenges, including increased incidence of allergic diseases and a limited number of allergy outpatient clinics. The article emphasizes that access to modern therapies and biological drugs that can significantly improve the quality of life of patients.
Aim:
The aim of the study is to analyse the implementation of allergy services, taking into account the number of drug programs, the value of contracts with the National Health Fund for conducting drug programs and the number of patients in drug programs.
Material And Methods:
The material and methods section includes publicly available data provided by the National Health Fund (NFZ), the Ministry of Health and the Central Statistical Office (GUS).
Conclusions:
The conclusions from the analysis indicate the dynamic development of drug programs in allergology, both in terms of the number of programs, the number of patients and the value of financing. The introduction of new programs, such as B.124 concerning the treatment of atopic dermatitis, shows that the healthcare system is trying to respond to the needs of patients and the appeals of the allergology community. At the same time, data published by the National Health Fund indicate growing queues of patients waiting for services, which shows that the waiting time for a visit in both outpatient and inpatient conditions is getting longer.
Related Concept Videos
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Drug Toxicity: Allergic Reactions
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...